Microbot Medical (MBOT) Stock Price

Microbot Medical Price

NASDAQ·CLOSED
1.72USD-0.02 (-1.16 %)
Market closed

Over the last 9 years Microbot Medical grew revenue by 2.6% annually, reaching 117,000.00 USD. For Microbot Medical, the net margin of -31,123.9% is down versus -1,746.8% a few years ago. The consensus 12-month price target for Microbot Medical is 5.10 USD, about 196.5% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 6% above its 52-week low.

Microbot Medical stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Microbot Medical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Microbot Medical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Microbot Medical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Microbot Medical Stock Price History
DateMicrobot Medical Price
7/31/20261.72 USD
7/30/20261.74 USD
7/29/20261.66 USD
7/27/20261.73 USD
7/23/20261.76 USD
7/22/20261.77 USD
7/21/20261.80 USD
7/20/20261.79 USD
7/17/20261.75 USD
7/16/20261.79 USD
7/15/20261.86 USD
7/14/20261.87 USD
7/13/20261.87 USD
7/10/20261.89 USD
7/9/20261.86 USD
7/8/20261.84 USD
7/7/20261.90 USD
7/6/20261.92 USD
7/2/20261.91 USD
7/1/20261.91 USD
6/30/20261.95 USD
6/29/20261.87 USD
6/26/20261.77 USD
6/25/20261.77 USD
6/24/20261.79 USD
6/23/20261.82 USD
6/22/20261.88 USD
6/18/20261.86 USD
6/17/20261.88 USD
6/16/20261.82 USD
6/15/20261.82 USD
6/12/20261.78 USD
6/11/20261.82 USD
6/10/20261.84 USD
6/9/20261.82 USD
6/8/20261.82 USD
6/5/20261.84 USD
6/4/20261.96 USD
6/3/20261.97 USD
6/2/20262.01 USD
6/1/20261.98 USD
5/29/20262.03 USD
5/28/20261.93 USD
5/27/20261.71 USD
5/26/20261.81 USD
5/22/20261.71 USD
5/21/20261.78 USD
5/20/20261.74 USD
5/19/20261.73 USD
5/18/20261.78 USD
5/15/20261.85 USD
5/14/20261.85 USD
5/13/20262.17 USD
5/12/20262.19 USD
5/11/20262.19 USD
5/8/20262.13 USD
5/7/20262.13 USD
5/5/20262.10 USD
4/23/20262.20 USD
4/22/20262.22 USD
4/21/20262.15 USD
4/20/20262.30 USD
4/17/20262.34 USD
4/16/20262.39 USD
4/15/20262.39 USD
4/14/20262.43 USD
4/13/20262.35 USD
4/10/20262.59 USD
4/9/20262.48 USD
4/8/20262.35 USD
4/7/20262.29 USD
4/6/20262.36 USD
4/2/20262.40 USD
4/1/20262.37 USD
3/31/20262.41 USD
3/30/20262.30 USD
3/27/20262.39 USD
3/26/20262.62 USD
3/25/20262.53 USD
3/24/20262.50 USD
3/23/20262.52 USD
3/20/20262.54 USD
3/19/20262.61 USD
3/18/20262.64 USD
3/17/20262.76 USD
3/16/20262.73 USD
3/13/20262.69 USD
3/12/20262.73 USD
3/11/20262.85 USD
3/10/20262.52 USD
3/9/20262.45 USD
3/6/20262.38 USD
3/5/20262.41 USD
3/4/20262.45 USD
3/3/20262.39 USD
3/2/20262.48 USD
2/27/20262.41 USD
2/26/20262.56 USD
2/25/20262.59 USD
2/24/20262.54 USD
2/23/20262.05 USD
2/20/20262.06 USD
2/19/20262.15 USD
2/18/20262.10 USD
2/17/20262.12 USD
2/13/20262.17 USD
2/12/20262.09 USD
2/11/20262.00 USD
2/10/20262.05 USD
2/9/20261.84 USD
2/6/20261.76 USD
2/5/20261.62 USD
2/4/20261.74 USD
2/3/20261.80 USD
2/2/20261.78 USD
1/30/20261.80 USD
1/29/20261.86 USD
1/28/20261.90 USD
1/27/20261.97 USD
1/26/20261.92 USD
1/23/20261.98 USD
1/22/20262.02 USD
1/21/20262.02 USD
1/20/20262.08 USD
1/16/20262.15 USD
1/15/20262.09 USD
1/14/20262.16 USD
1/13/20262.12 USD
1/12/20262.13 USD
1/9/20262.09 USD
1/8/20262.19 USD
1/7/20262.11 USD
1/6/20262.13 USD
1/5/20262.09 USD
1/2/20262.11 USD
12/31/20252.00 USD
12/30/20252.05 USD
12/29/20252.11 USD
12/26/20252.15 USD
12/24/20252.18 USD
12/23/20252.18 USD
12/22/20252.19 USD
12/19/20252.08 USD
12/18/20252.07 USD
12/17/20252.04 USD
12/16/20252.22 USD
12/15/20252.21 USD
12/12/20252.41 USD
12/11/20252.38 USD
12/10/20252.40 USD
12/9/20252.46 USD
12/8/20252.36 USD
12/5/20252.37 USD
12/4/20252.46 USD
12/3/20252.49 USD
12/2/20252.21 USD
12/1/20252.26 USD
11/28/20252.42 USD
11/26/20252.29 USD
11/25/20251.88 USD
11/24/20251.92 USD
11/21/20251.83 USD
11/20/20251.73 USD
11/19/20251.92 USD
11/18/20252.00 USD
11/17/20252.02 USD
11/14/20252.07 USD
11/13/20251.99 USD
11/12/20252.12 USD
11/11/20252.09 USD
11/10/20252.09 USD
11/7/20252.05 USD
11/6/20252.03 USD
11/5/20252.12 USD
11/4/20252.02 USD
11/3/20252.12 USD
10/31/20252.23 USD
10/30/20252.16 USD
10/29/20252.13 USD
10/28/20252.19 USD
10/27/20252.39 USD
10/24/20252.42 USD
10/23/20252.47 USD
10/22/20252.51 USD
10/21/20252.67 USD
10/20/20252.80 USD
10/17/20252.76 USD
10/16/20252.84 USD
10/15/20252.92 USD
10/14/20252.88 USD
10/13/20253.01 USD
10/10/20252.92 USD
10/9/20253.17 USD
10/8/20253.29 USD
10/7/20253.23 USD
10/6/20253.22 USD
10/3/20253.07 USD
10/2/20253.17 USD
10/1/20253.16 USD
9/30/20253.05 USD
9/29/20253.20 USD
9/26/20253.22 USD
9/25/20253.29 USD
9/24/20253.35 USD
9/23/20253.48 USD
9/22/20253.31 USD
9/19/20253.19 USD
9/18/20253.09 USD
9/17/20253.32 USD
9/16/20253.34 USD
9/15/20253.42 USD
9/12/20254.05 USD
9/11/20253.89 USD
9/10/20253.57 USD
9/9/20253.85 USD
9/8/20254.50 USD
9/5/20253.66 USD
9/4/20253.37 USD
9/3/20253.54 USD
9/2/20253.75 USD
8/29/20253.81 USD
8/28/20254.00 USD
8/27/20254.07 USD
8/26/20253.88 USD
8/25/20254.16 USD
8/22/20253.85 USD
8/21/20253.56 USD
8/20/20253.31 USD
8/19/20253.09 USD
8/18/20253.08 USD
8/15/20253.09 USD
8/14/20253.13 USD
8/13/20253.04 USD
8/12/20253.12 USD
8/11/20252.89 USD
8/8/20253.09 USD
8/7/20252.92 USD
8/6/20252.87 USD
8/5/20252.88 USD
8/4/20252.65 USD
Access this data via the Eulerpool API
Get Free API Key

Microbot Medical Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
0.00 USD
-13.28 M USD
-13.17 M USD
Jan 1, 2023
0.00 USD
-9.86 M USD
-10.74 M USD
Jan 1, 2024
0.00 USD
-11.63 M USD
-11.44 M USD
Jan 1, 2025
0.00 USD
-14.74 M USD
-13.14 M USD
Jan 1, 2026 (e)
2.83 M USD
-25.56 M USD
-4.38 M USD
Jan 1, 2027 (e)
8.90 M USD
-24.29 M USD
-4.64 M USD
Jan 1, 2028 (e)
24.00 M USD
0.00 USD
-3.21 M USD
Jan 1, 2029 (e)
47.60 M USD
-3.77 M USD
469,335.00 USD

Microbot Medical Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 3, 2026, 3:29 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
1.00–––––––––––2.008.0024.0047.00
–––––––––––––300.00200.0095.83
100.00–––––––––––100.00100.00100.00100.00
1.001.001.001.001.001.001.001.001.001.001.001.002.008.0024.0047.00
-30.00-36.00-9.00-5.00-7.00-7.00-9.00-11.00-13.00-9.00-11.00-14.00-25.00-24.00–-3.00
-3,000.00–––––––––––-1,250.00-300.00–-6.38
-32.00-36.00-9.00-7.00-7.00-7.00-9.00-11.00-13.00-10.00-11.00-13.00-4.00-4.00-3.00–
23.0812.50-75.00-22.22––28.5722.2218.18-23.0810.0018.18-69.23–-25.00–
0.040.072.182.764.097.157.117.117.7212.1317.0267.1667.1667.1667.1667.16
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Microbot Medical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Microbot Medical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Microbot Medical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Microbot Medical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Microbot Medical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Microbot Medical stock margins

The Microbot Medical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Microbot Medical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Microbot Medical.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
100.00 %
- %
- %
Jan 1, 2022
100.00 %
- %
- %
Jan 1, 2023
100.00 %
- %
- %
Jan 1, 2024
100.00 %
- %
- %
Jan 1, 2025
100.00 %
- %
- %
Jan 1, 2026 (e)
100.00 %
-904.65 %
-155.06 %
Jan 1, 2027 (e)
100.00 %
-272.90 %
-52.15 %
Jan 1, 2028 (e)
100.00 %
0.00 %
-13.36 %

Microbot Medical Stock Revenue, EBIT, Earnings per Share

The Microbot Medical earnings per share therefore indicates how much revenue Microbot Medical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 USD
-1.60 USD
-1.59 USD
Jan 1, 2022
0.00 USD
-1.72 USD
-1.71 USD
Jan 1, 2023
0.00 USD
-0.81 USD
-0.89 USD
Jan 1, 2024
0.00 USD
-0.68 USD
-0.67 USD
Jan 1, 2025
0.00 USD
-0.22 USD
-0.20 USD
Jan 1, 2026 (e)
0.18 USD
-0.38 USD
-0.28 USD
Jan 1, 2027 (e)
0.57 USD
-0.36 USD
-0.30 USD
Jan 1, 2028 (e)
1.53 USD
0.00 USD
-0.21 USD

Microbot Medical business model & stock analysis

Microbot Medical Inc. is a leading company in the development of microrobots for the medical field. The company was established in 2010 and is headquartered in Hingham, Massachusetts. Microbot Medical Inc. believes that the future of medicine lies in robotics and specializes in developing innovative solutions for complex surgical procedures and minimally invasive interventions. The company's business model is based on the development and commercialization of intelligent microrobots that will enable more precise and gentle surgical interventions. From the beginning, the company has focused on two main areas: the development of robot-assisted systems for neurosurgical procedures and the development of solutions for gastroenterology applications. In the field of neurosurgical procedures, Microbot Medical Inc. has developed the LIBERTY robot for market readiness. This robot is designed to assist surgeons during neurosurgical procedures that require increased precision and effectiveness. The robot aids the surgeon in navigating difficult-to-access areas of the brain and can help minimize the risk of tissue damage. Microbot Medical Inc. is also a leader in the development of robots in the gastroenterology field. The company has introduced the SELF-TESTER robot, which is capable of performing endoscopies in a more comfortable and painless manner. The SELF-TESTER is navigated through the digestive system and can help diagnose diseases such as cancer or inflammations in the gastrointestinal tract more effectively. Furthermore, Microbot Medical Inc. conducts research and development activities in the field of cardiovascular surgery. The company is working on a solution that allows doctors to implant aortic valves minimally invasively. The goal is to create an alternative to traditional open-heart surgery. The company has also signed a letter of intent with Cardiovascular Systems Inc. to jointly bring a new product to market that has the potential to further accelerate the minimally invasive aortic valve implantation procedure. In recent years, Microbot Medical Inc. has received several awards and recognitions, including an award from Frost & Sullivan in the category of "New Product Innovation." The company has also formed important partnerships with other leaders in the medical technology field to support the development and commercialization of its products. In conclusion, Microbot Medical Inc. is one of the leading providers of intelligent robots for the medical field and will play an important role in the development of advanced technologies that contribute to making surgical interventions more effective and safer in the coming years. The company is committed to driving innovations in medical technology and has already made a name for itself by successfully developing products in various areas.

Microbot Medical SWOT Analysis

Strengths

  • Proprietary technology: Microbot Medical Inc has developed unique and innovative technology in the field of medical robotics.
  • Strong intellectual property: The company holds a significant number of patents and intellectual property rights, providing a competitive advantage.
  • Strong management team: Microbot Medical Inc is led by experienced and skilled professionals in the medical device industry, ensuring effective execution of strategies.
  • Strong financial position: The company has a solid financial foundation, with sufficient funds to support ongoing research, development, and commercialization efforts.
  • Strategic partnerships: Microbot Medical Inc has established partnerships with leading healthcare organizations and research institutions, facilitating access to resources and expertise.

Weaknesses

  • Limited product portfolio: As a relatively small company, Microbot Medical Inc currently has a limited range of products in its portfolio.
  • Reliance on regulatory approvals: The company's success is dependent on obtaining necessary regulatory approvals, which can be time-consuming and uncertain.
  • Lack of brand recognition: Microbot Medical Inc is still establishing itself in the market and faces challenges in building brand awareness and customer trust.
  • Limited market presence: The company's products may not be widely known or available, resulting in limited market penetration.
  • Dependency on key suppliers: Microbot Medical Inc relies on specific suppliers for crucial components, which could pose a risk in terms of supply chain disruptions.

Opportunities

  • Growing demand for minimally invasive procedures: Microbot Medical Inc can capitalize on the increasing trend toward minimally invasive surgeries, offering potential growth opportunities.
  • Aging population and chronic disease prevalence: The rise in aging population and associated chronic diseases presents a significant market opportunity for the company's medical devices.
  • Expansion into new markets: Microbot Medical Inc can explore expansion into international markets, further increasing its potential customer base.
  • Collaborations and partnerships: The company can seek collaborations with industry leaders, research institutions, and healthcare providers to enhance its product development and market reach.
  • Technological advancements: Continuous advancements in technology open doors for Microbot Medical Inc to develop new and improved medical devices.

Threats

  • Intense competition: The medical device industry is highly competitive, and Microbot Medical Inc faces competition from established players as well as emerging startups.
  • Stringent regulatory environment: Compliance with rigorous regulatory standards and requirements can pose challenges and delays in product development and commercialization.
  • Economic uncertainties: Volatile economic conditions and healthcare funding constraints could impact the company's market opportunities and revenue growth.
  • Rapid technological advancements: The fast-paced nature of technological advancements means that Microbot Medical Inc needs to continuously innovate to stay ahead of competitors.
  • Reimbursement challenges: The company may face challenges in securing favorable reimbursement for its products from insurance companies and healthcare systems.

Microbot Medical Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Microbot Medical Employees
Details
Date
Microbot Medical Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Microbot Medical Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Microbot Medical historical P/E ratio, EBIT multiple, and P/S ratio

Microbot Medical annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Microbot Medical shares outstanding

The number of shares of Microbot Medical was 67.16 M in 2025. This indicates how many shares Microbot Medical is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
7.11 M Stocks
Jan 1, 2022
7.72 M Stocks
Jan 1, 2023
12.13 M Stocks
Jan 1, 2024
17.02 M Stocks
Jan 1, 2025
67.16 M Stocks
Jan 1, 2026 (e)
67.16 M Stocks
Jan 1, 2027 (e)
67.16 M Stocks
Jan 1, 2028 (e)
67.16 M Stocks

Microbot Medical stock splits

In Microbot Medical's history, there have been no stock splits.

Current Microbot Medical forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
33.33 %
Buy
87.50 % (7)
Hold
12.50 % (1)
Sell
0.00 % (0)
12M Price Target
5.10
Last Price
1.72
Currency
USD
12M Return Potential
196.51 %
LTM Return
0 %

Microbot Medical Analyst Rating Actions

DateFirmActionRating
4/14/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
11/28/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
10/15/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
9/11/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
4/10/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
1/24/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
6/3/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
4/16/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
10/18/2023
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
6/26/2023
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy

Microbot Medical Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/10/2026-0.08USD-346,800.00USD-2026 Q2
5/12/2026-0.08USD-306,000.00USD-2026 Q1
3/23/2026-0.06USD-102,000.00USD-2025 Q4
8/12/2025-0.08USD-0.00USD-2025 Q2
11/12/2024-0.17USD-0.00USD-2024 Q3
5/15/2024-0.19USD--USD-2024 Q1
3/29/2024-0.26USD-0.00USD-2023 Q4
8/14/2023-0.43USD--USD-2023 Q2
5/15/2023-0.48USD--USD-2023 Q1
3/29/2023-0.53USD-0.00USD-2022 Q4

Microbot Medical shareholder structure

% Name
21.28365%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
9.46019%
CIBC Private Wealth Management
CIBC Private Wealth Management
7.95885%
Susquehanna International Group, LLP
Susquehanna International Group, LLP
5.20449%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
4.87069%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
4.33058%
DNB Asset Management AS
DNB Asset Management AS
...

Microbot Medical Beneficial Ownership Filings (SEC 13D/G)

Free Float
99.9%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
19.47%
Yoseph Bornstein
Yoseph Bornstein
SEC ↗
19.47%
LSA- Life Science Accelerator Ltd.
LSA- Life Science Accelerator Ltd.
SEC ↗
15.90%
Merrill Lynch Growth Fund for Investment & Retirement
Merrill Lynch Growth Fund for Investment & Retirement
SEC ↗
15.50%
Princeton Services, Inc.
Princeton Services, Inc.
SEC ↗
15.50%
Merril Lynch Growth Fund
Merril Lynch Growth Fund
SEC ↗
15.50%
Merrill Lynch Asset Management, L.P.
Merrill Lynch Asset Management, L.P.
SEC ↗
12.94%
Berkson
Berkson
SEC ↗
11.00%
Scudder, Stevens & Clark, Inc.
Scudder, Stevens & Clark, Inc.
SEC ↗
10.00%
Millennium Management LLC
Millennium Management LLC
SEC ↗
10.00%
Millennium International Management LP
Millennium International Management LP
SEC ↗

Microbot Medical Executives and Management Board

10 members · avg. age 57 · 20 % women

HG

Mr. Harel Gadot (53)

Chairman of the Board, President, Chief Executive Officer · since 2016

1.24 M USD

Management

SS

Mr. Simon Sharon (64)

Chief Technology Officer, General Manager of Microbot Israel

539,429.00 USD
JD

Dr. Juan Diaz-Cartelle (48)

Chief Medical Officer

376,478.00 USD
RV

Ms. Rachel Vaknin (46)

Chief Financial Officer

363,165.00 USD

Board of Directors

SB

Mr. Scott Burell (60)

Independent Director

111,891.00 USD
MM

Mr. Martin Madden (64)

Independent Director

111,891.00 USD
PL

Mr. Prattipati Laxminarain (67)

Independent Director

100,641.00 USD
AS

Ms. Aileen Stockburger (62)

Independent Director

98,766.00 USD
TW

Mr. Tal Wenderow (51)

Independent Director

96,891.00 USD
DW

Mr. David Wilson (57)

Independent Director

–

Frequently asked questions about Microbot Medical

Microbot Medical Inc's business model focuses on the development and commercialization of innovative transformational robotic solutions in the medical industry. The company specializes in creating miniature robots that can assist in minimally invasive surgeries, targeted drug delivery, and targeted endotherapy procedures. Microbot Medical Inc utilizes its proprietary technologies, including its Microbot Swarm system and ViRob robotic platform, to address critical unmet needs in various medical specialties. With its advanced robotic solutions, Microbot Medical Inc aims to improve patient outcomes, enhance surgical procedures, and provide physicians with more precise and efficient tools for diagnosis and treatment in the medical field.

Microbot Medical Inc is primarily active in the medical technology industry. As a cutting-edge company, Microbot Medical specializes in the development and commercialization of robotic technologies focused on improved medical procedures and treatments. With its innovative product portfolio, Microbot Medical aims to revolutionize various medical fields such as urology, neurology, and cardiovascular healthcare. Through its dedication to technological advancements and industry collaborations, Microbot Medical strives to provide healthcare professionals and patients with breakthrough solutions that enhance overall medical outcomes.

The main competitors of Microbot Medical Inc in the market include companies such as Medtronic, Intuitive Surgical, and Johnson & Johnson.

Microbot Medical Inc is a leading medical device company specializing in the development of transformational micro-robotic technologies. Established in 2010, Microbot Medical Inc aims to improve patient outcomes through the development of innovative robotic platforms designed for minimally invasive surgeries and targeted therapies. The company's cutting-edge technologies utilize advanced engineering and robotics to address significant unmet medical needs in various medical fields, including urology, gastroenterology, and ENT (ear, nose, and throat). With its commitment to revolutionizing medical interventions, Microbot Medical Inc continues to push boundaries in the field of robotic medicine, creating new possibilities for improved patient care.

Microbot Medical Inc has achieved several significant milestones. Firstly, the company successfully developed and received regulatory clearance for its innovative robotic technologies in the medical industry. Additionally, Microbot Medical Inc has made notable advancements in the fields of urology, neurology, and gastrointestinal procedures. The company has also successfully completed important clinical studies and collaborations with leading medical institutions. Moreover, Microbot Medical Inc has secured intellectual property rights for its proprietary technologies, which strengthens its position in the market. These milestones demonstrate the company's dedication to improving healthcare outcomes and solidify its reputation as a leader in the medical robotics field.

Microbot Medical Inc is primarily present in the United States, Israel, and Europe. This company, specializing in micro-robotics technologies, operates in multiple regions to distribute their innovative medical devices and solutions. Microbot Medical Inc's presence in these countries and regions enables them to reach a significant market and collaborate with leading medical institutions, professionals, and industry experts. By establishing a global footprint, Microbot Medical Inc aims to enhance patient outcomes and revolutionize the field of medical robotics.

Microbot Medical Inc represents values of innovation, advancement, and patient-centric healthcare solutions. With a strong corporate philosophy aimed at addressing unmet medical needs, Microbot Medical Inc is dedicated to developing and commercializing transformative robotic technologies. By combining novel engineering with medical expertise, the company aims to improve patient outcomes, reduce healthcare costs, and enhance overall quality of life. Microbot Medical Inc strives to empower physicians and healthcare professionals with cutting-edge tools and solutions, all while prioritizing patient safety and well-being.

Analysts currently set an average price target of 6.80 USD for the Microbot Medical stock (median: 5.10 USD), implying +295.4 % versus the latest price. The consensus is based on 8 analyst ratings.

Microbot Medical Analyst Price Targets 2026

9 analysts currently rate the Microbot Medical stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Microbot Medical to generate revenue of 2.83 M USD and earnings per share of -0.07 USD.

Microbot Medical Analyst Price Targets 2026

Converted at the current exchange rate, the Microbot Medical share trades at 1.49 EUR (1.72 USD).

The Microbot Medical share (MBOT) is listed on 4 stock exchanges, including: NASDAQ (MBOT), Frankfurt (CY9D.F), München (CY9D.MU), Düsseldorf (CY9D.DU).

Microbot Medical Inc is a leading company in the development and commercialization of miniature robots for medical applications. The company is based in Israel and also has branches in the USA.

The expected revenue of Microbot Medical is 2.83 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Microbot Medical is -4.38 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Microbot Medical is currently -26.37. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Microbot Medical stock.

The price-to-sales ratio (P/S) of Microbot Medical is currently 40.89. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Microbot Medical stock.

The Eulerpool Quality Score for Microbot Medical is 2/10.

The ISIN of Microbot Medical is US59503A2042. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Microbot Medical is A2N5AS. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Microbot Medical is MBOT. The ticker symbol is used to trade Microbot Medical shares on the stock exchange.

Microbot Medical paid dividends every year for the past 0 years.

Microbot Medical is assigned to the 'Health' sector.

The dividends of Microbot Medical are distributed in USD.

All fundamentals and in-depth analysis of Microbot Medical

Our stock analysis for Microbot Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Microbot Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Microbot Medical Stock
Microbot Medical Revenue→
Microbot Medical Stock
Microbot Medical Net Income→
Microbot Medical Stock
Microbot Medical P/E→
Microbot Medical Stock
Microbot Medical P/S→
Microbot Medical Stock
Microbot Medical EBIT→
Microbot Medical Stock
Microbot Medical Dividend→
Microbot Medical Stock
Microbot Medical Directors Dealings→
Microbot Medical Stock
Microbot Medical Stocks→
Microbot Medical Stock
Microbot Medical Market capitalization→
Microbot Medical Stock
Microbot Medical Debt→
Microbot Medical Stock
Microbot Medical Liabilities→
Microbot Medical Stock
Microbot Medical Equity→
Microbot Medical Stock
Microbot Medical AAQS→
Microbot Medical Stock
Microbot Medical Employees→
Microbot Medical Stock
Microbot Medical ROE→
Microbot Medical Stock
Microbot Medical ROA→
Microbot Medical Stock
Microbot Medical ROCE→
Microbot Medical Stock
Microbot Medical News→
Microbot Medical Stock
Microbot Medical Analyst Price Targets→

Health Stocks

Micron SolutionsMicrobix BiosystemsMicroport Cardioflow MedtechMicroBase TechnologyMicroPort NeuroScientificMicroba Life SciencesMicropos Medical AB (publ)Micro-XMicroTech Medical (Hangzhou) CoMicro-Tech Nanjing CoMiddle East Healthcare Company SJSCMicro Digital CoAll Stocks A–Z →